JP7709454B2 - トリアゾロン化合物 - Google Patents

トリアゾロン化合物

Info

Publication number
JP7709454B2
JP7709454B2 JP2022558348A JP2022558348A JP7709454B2 JP 7709454 B2 JP7709454 B2 JP 7709454B2 JP 2022558348 A JP2022558348 A JP 2022558348A JP 2022558348 A JP2022558348 A JP 2022558348A JP 7709454 B2 JP7709454 B2 JP 7709454B2
Authority
JP
Japan
Prior art keywords
pyrimidin
triazolo
amino
methyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022558348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519363A5 (https=
JP2023519363A (ja
Inventor
アルバート ブラウン，ジレス
スチュアート コングリーブ，マイルズ
フィリップ アンドリューズ，スティーブン
スティーブン メイソン，ジョナサン
デフロリアン，フランチェスカ
アラン スウェイン，ナイジェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of JP2023519363A publication Critical patent/JP2023519363A/ja
Publication of JP2023519363A5 publication Critical patent/JP2023519363A5/ja
Application granted granted Critical
Publication of JP7709454B2 publication Critical patent/JP7709454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022558348A 2020-03-26 2021-03-25 トリアゾロン化合物 Active JP7709454B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994954P 2020-03-26 2020-03-26
US62/994,954 2020-03-26
PCT/EP2021/057808 WO2021191380A1 (en) 2020-03-26 2021-03-25 Triazolone compounds

Publications (3)

Publication Number Publication Date
JP2023519363A JP2023519363A (ja) 2023-05-10
JP2023519363A5 JP2023519363A5 (https=) 2024-04-01
JP7709454B2 true JP7709454B2 (ja) 2025-07-16

Family

ID=75302568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558348A Active JP7709454B2 (ja) 2020-03-26 2021-03-25 トリアゾロン化合物

Country Status (8)

Country Link
US (1) US12552799B2 (https=)
EP (1) EP4126871B1 (https=)
JP (1) JP7709454B2 (https=)
KR (1) KR20230049580A (https=)
CN (1) CN115867550B (https=)
AU (1) AU2021241886A1 (https=)
CA (1) CA3177057A1 (https=)
WO (1) WO2021191380A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138734A1 (en) 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
WO2018184590A1 (zh) 2017-04-07 2018-10-11 南京明德新药研发股份有限公司 作为A 2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
WO2019196803A1 (en) 2018-04-08 2019-10-17 Beigene, Ltd. Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
AU2011306358B2 (en) 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
AU2018233367B2 (en) 2017-03-16 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138734A1 (en) 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
WO2018184590A1 (zh) 2017-04-07 2018-10-11 南京明德新药研发股份有限公司 作为A 2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
WO2019196803A1 (en) 2018-04-08 2019-10-17 Beigene, Ltd. Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors

Also Published As

Publication number Publication date
JP2023519363A (ja) 2023-05-10
KR20230049580A (ko) 2023-04-13
EP4126871B1 (en) 2024-05-08
US20230146796A1 (en) 2023-05-11
WO2021191380A1 (en) 2021-09-30
US12552799B2 (en) 2026-02-17
AU2021241886A1 (en) 2022-10-27
EP4126871A1 (en) 2023-02-08
CN115867550B (zh) 2025-01-03
CN115867550A (zh) 2023-03-28
CA3177057A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2019243289B2 (en) Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
JP6159028B2 (ja) Ｓｙｋ阻害剤
CN117957226A (zh) 作为sos1抑制剂的杂环化合物及其用途
CN114539245A (zh) 含嘧啶并环类衍生物调节剂、其制备方法和应用
EP2435438A1 (en) Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
JP2024502097A (ja) 三環式化合物とその用途
JP7709454B2 (ja) トリアゾロン化合物
JP7675094B2 (ja) トリアゾロン化合物
CN115867280B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
HK40088927A (en) Triazolone compounds
HK40088927B (en) Triazolone compounds
HK40069226A (en) Pyrimidine-fused ring derivative regulator, a method for preparing the same and use thereof
EA041815B1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
HK40049450B (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HK40049450A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250704

R150 Certificate of patent or registration of utility model

Ref document number: 7709454

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150